Rabia Gurses Ozden - 17 Jun 2025 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
Chief Medical Officer
Signature
/s/ Aneta Fergson, Attorney-in-Fact
Issuer symbol
ADVM
Transactions as of
17 Jun 2025
Net transactions value
$0
Form type
4
Filing time
20 Jun 2025, 16:28:01 UTC
Previous filing
27 Feb 2025
Next filing
10 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ozden Rabia Gurses Chief Medical Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY /s/ Aneta Fergson, Attorney-in-Fact 20 Jun 2025 0001814883

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADVM Stock Option (Right to Buy) Disposed to Issuer $0 -8,000 -100% $0.000000 0 17 Jun 2025 Common Stock 8,000 $13.50 Direct F1, F2
transaction ADVM Stock Option (Right to Buy) Award $0 +8,000 $0.000000 8,000 17 Jun 2025 Common Stock 8,000 $10.14 Direct F1, F2
transaction ADVM Stock Option (Right to Buy) Disposed to Issuer $0 -4,000 -100% $0.000000 0 17 Jun 2025 Common Stock 4,000 $15.60 Direct F1, F3
transaction ADVM Stock Option (Right to Buy) Award $0 +4,000 $0.000000 4,000 17 Jun 2025 Common Stock 4,000 $10.14 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective March 21, 2024, the Issuer effected a reverse stock split (the "Reverse Split") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten.
F2 The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on March 17, 2022 and is fully vested.
F3 The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 9, 2023 and is fully vested.